See more : Zioncom Holdings Limited (8287.HK) Income Statement Analysis – Financial Results
Complete financial analysis of PAVmed Inc. (PAVM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAVmed Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Eutelsat Communications S.A. (ETL.L) Income Statement Analysis – Financial Results
- Fidelis Energy, Inc. (FDEI) Income Statement Analysis – Financial Results
- Guangzhou Jiacheng International Logistics Co.,Ltd. (603535.SS) Income Statement Analysis – Financial Results
- Nanjing Xinlian Electronics Co., Ltd (002546.SZ) Income Statement Analysis – Financial Results
- Oneness Biotech Co., Ltd. (4743.TWO) Income Statement Analysis – Financial Results
PAVmed Inc. (PAVM)
About PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.45M | 377.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.42M | 3.61M | 585.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 0.00 | 0.00 |
| Gross Profit | -3.97M | -3.24M | -85.00K | -23.00K | -14.23K | -9.79K | -7.11K | -3.79K | 0.00 | 0.00 |
| Gross Profit Ratio | -161.83% | -858.62% | -17.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.28M | 25.55M | 19.85M | 10.96M | 6.63M | 4.25M | 2.62M | 1.72M | 489.33K | 22.29K |
| General & Administrative | 30.95M | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 0.00 |
| Selling & Marketing | 17.58M | 19.32M | 8.90M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.53M | 60.36M | 34.46M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 400.00K |
| Other Expenses | 2.02M | 1.78M | 0.00 | 0.00 | -558.60K | -903.00K | -3.12M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.83M | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Cost & Expenses | 71.25M | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Interest Income | 505.00K | 1.27M | 0.00 | 53.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 589.00K | 1.27M | 0.00 | 53.00K | 32.67K | 2.39M | 724.68K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93M | 2.55M | 226.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 1.78M | 422.29K |
| EBITDA | -75.74M | -99.41M | -55.90M | -35.81M | -16.67M | -12.07M | -11.15M | -5.65M | -1.78M | -126.48K |
| EBITDA Ratio | -3,088.99% | -24,615.92% | -10,833.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.80M | -90.93M | -54.39M | -23.35M | -14.30M | -10.56M | -8.03M | -5.65M | -1.78M | -422.29K |
| Operating Income Ratio | -2,805.67% | -24,118.57% | -10,878.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.47M | -12.15M | -1.73M | -12.54M | -2.97M | -7.61M | -1.49M | 0.00 | 0.00 | -126.48K |
| Income Before Tax | -79.26M | -103.24M | -56.13M | -35.89M | -17.27M | -18.17M | -9.52M | -5.65M | -1.78M | -548.77K |
| Income Before Tax Ratio | -3,232.59% | -27,384.08% | -11,225.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -5.78M | -1.56M | -1.34M | -204.07K | 878.87K | -1.00 | -1.78M | -126.48K |
| Net Income | -64.18M | -101.29M | -50.35M | -34.33M | -15.93M | -17.97M | -9.52M | -5.65M | -1.78M | -548.77K |
| Net Income Ratio | -2,617.25% | -26,868.44% | -10,069.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| EPS Diluted | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| Weighted Avg Shares Out | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
| Weighted Avg Shares Out (Dil) | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
First patients enrolled on the Veris Cancer Care Platform NEW YORK , June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and...
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...
PAVmed Provides Business Update and First Quarter 2024 Financial Results
Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT...
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated...
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication further strengthens EsoGuard's clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage NEW YORK...
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK , April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN)...
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.
PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript
PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports